Acorda Therapeutics (ACOR) - Get Report was upgraded to neutral from sell at Goldman Sachs. $22 price target. Parkinson's data has been improving, Goldman said.
First Data (FDC) - Get Report was initiated with a hold rating at TheStreet Ratings. You can view the full analysis from the report here: FDC.
Nordson (NDSN) - Get Report was upgraded to overweight at Keybanc. $135 price target. Strong global CapEx cycle should drive upside to expectations, Keybanc said.
Parker Hannifin (PH) - Get Report was upgraded to buy from neutral at Bank of America/Merrill Lynch. $180 price target. The company has cyclical, execution and acquisition upside, analysts said.
Restoration Hardware (RH) - Get Report was upgraded to overweight at Keybanc. $34 price target. Sentiment has been washed out, but fundamentals should improve in the coming quarters, Keybanc said.
Stock Comments/EPS Changes
Shares of Humana (HUM) - Get Report are now seen reaching $220, according to Credit Suisse. Earnings estimates were also increased, as the company offered solid guidance following the loss of the Aetna deal. The analyst has an outperform rating.
Shares of Merck (MRK) - Get Report are now seen reaching $70, according to BMO Capital. The Epoch trial had disappointing results. The analyst has an outperform rating.
This article was written by a staff member of TheStreet.